Clinical Research Directory

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults more than 60 years and older with peripheral artery disease (PAD) who have undergone infrainguinal endovascular surgery. The main questions it aims to answer are: * Does TEG-PM-guided antiplatelet therapy lower the rate of thrombosis or clinically significant stenosis of the treated artery within 12 months compared with a historical standard-of-care cohort? * How does TEG-PM-guided therapy affect major amputation, amputation-free survival, mortality, and bleeding? Participants will: * Have blood samples taken before the procedure and at 1, 3, and 6 months afterward * Have antiplatelet medications (aspirin, clopidogrel, and/or ticagrelor) escalated or de-escalated based on TEG-PM results through 6 months * Have one additional blood test to check clopidogrel response if taking clopidogrel * Be followed for clinical outcomes through 12 months

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs. The main questions it aims to answer are: * Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure? * Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment? Researchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better. Participants will: * Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure * Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure * Have medications adjusted based on blood test results if assigned to the TARGET group